Publication:
Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment

Simple item page
dc.contributor.authorAKIN TELLİ, TUĞBA
dc.contributor.authorÖZGÜVEN, SALİH
dc.contributor.authorFİLİZOĞLU, NUH
dc.contributor.authorÖZTÜRK, MEHMET SAADEDDİN
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorDEMİRCAN, NAZIM CAN
dc.contributor.authorBAŞOĞLU TÜYLÜ, TUĞBA
dc.contributor.authorALSAN ÇETİN, İLKNUR
dc.contributor.authorÖNEŞ, TUNÇ
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsAKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al.
dc.date.accessioned2022-10-04T11:04:57Z
dc.date.available2022-10-04T11:04:57Z
dc.date.issued2022-08-01
dc.description.abstractObjective We aimed to evaluate whether baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and methods This retrospective study included 54 mCRPC patients, who underwent baseline Ga-68-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of >= 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001-1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189-4.222, p = 0.01) as independent predictors of OS. Conclusion The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC.
dc.identifier.citationAKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al., "Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment", ANNALS OF NUCLEAR MEDICINE, 2022
dc.identifier.doi10.1007/s12149-022-01785-x
dc.identifier.issn0914-7187
dc.identifier.urihttps://hdl.handle.net/11424/282075
dc.language.isoeng
dc.relation.ispartofANNALS OF NUCLEAR MEDICINE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectNükleer Tıp
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectNuclear medicine
dc.subjectHealth Sciences
dc.subjectRADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectRadyoloji ve Ultrason Teknolojisi
dc.subjectRadyoloji, Nükleer Tıp ve Görüntüleme
dc.subjectRadiological and Ultrasound Technology
dc.subjectRadiology, Nuclear Medicine and Imaging
dc.subjectGa-PSMA PET/CT · Metastatic castration-resistant prostate cancer · Survival · Whole-body volumetric parameters
dc.titleRole of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
dc.typearticle
dspace.entity.typePublication
local.avesis.id21338367-10b3-430d-9a76-a3b9326e7375
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication634579fc-78dd-43c6-b231-31cf08aea852
relation.isAuthorOfPublication38325c3e-4399-4724-947c-39953f47fcae
relation.isAuthorOfPublication8437606f-4783-48d0-a3c2-57db652ff489
relation.isAuthorOfPublication4a323dc3-ca3e-4852-b955-3207503c1e5b
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication8471e450-fb45-4e21-ab29-49db25acbf9a
relation.isAuthorOfPublicationddaeb928-6e68-4414-bd70-00515b6656a6
relation.isAuthorOfPublicationfab5ec4d-b078-4832-a240-29c00f3c424c
relation.isAuthorOfPublication98e10a59-a9b0-4f53-894f-be262c4d54f8
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscovery634579fc-78dd-43c6-b231-31cf08aea852

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
3.pdf
Size:
909.75 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs